MicroRNAs can regulate human APP levels
© Patel et al; licensee BioMed Central Ltd. 2008
Received: 21 July 2008
Accepted: 06 August 2008
Published: 06 August 2008
A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD). Therefore, understanding how APP levels are regulated could provide valuable insight into the genetic basis of AD and illuminate novel therapeutic avenues for AD. Here we test the hypothesis that APP protein levels can be regulated by miRNAs, evolutionarily conserved small noncoding RNA molecules that play an important role in regulating gene expression. Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression. Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels. These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.
Accumulating evidence suggests that increased expression of the amyloid precursor protein gene (APP) increases Alzheimer's disease (AD) risk. The resulting increase in APP protein levels results in increased Aβ levels, leading to synaptic dysfunction, neurodegeneration and, eventually, cognitive decline.
APP levels can be regulated at the genomic, transcriptional or translational level. At the genomic level, Down's Syndrome (Trisomy 21) patients have three copies of the APP gene and develop AD symptoms early in life . Similarly, duplication of the APP locus, in the absence of a full trisomy 21, also leads to early-onset AD . Dysregulation of APP transcription can also increase the risk of AD. Genetic variants in the APP promoter increase APP transcription by ~2–3 fold and have been reported to increase AD risk . Growth factors have been reported to control APP mRNA half-life . These growth factors effects are dependent on a 29 bp sequence in the APP 3' UTR [4, 5]. APP translation is also regulated; for example, IL-1 can induce an increase in APP translation . IL-1 is a pro-inflammatory cytokine and genetic variants have been linked to increased AD risk [7, 8]. Taken together, these findings provide strong evidence that increased APP levels increase AD risk.
MicroRNAs (miRNAs) are small noncoding RNAs that control gene expression post-transcriptionally. Complementary binding between miRNAs and sequences within the 3' UTR of target genes results in repression of target gene expression by translational inhibition or mRNA degradation . Approximately 700 miRNA genes are encoded in the human genome and recent evidence demonstrates that some miRNAs are differentially expressed in AD patients compared to age-matched controls . These differences in miRNA expression may play an important role in AD pathogenesis. In an attempt to address this possibility, we test the hypothesis that miRNAs can regulate APP levels.
Relative miRNA levels
Fold Change 2-ΔΔCt
30.1 ± 1.2
1964.6 ± 1.1
Most human miRNAs repress gene expression by inhibiting translation and do not affect target gene mRNA levels [15, 16]. This seems to be the case in our experimental setting. We utilized RT-QPCR to determine if miRNA over-expression resulted in decreased APP mRNA levels. Over-expression of mir-106a or mir-520c had no effect on APP mRNA levels (Figure 2E). Mir-106a and mir-520c, therefore, appear to inhibit translation of the APP transcript.
Our results are the first to experimentally demonstrate that human APP levels can be regulated by miRNAs. In 2004, it was predicted that APP levels could be regulated by miRNAs ; recently it was shown that expression of the C. elegans orthologue of APP, APL-1, is regulated by developmentally-timed miRNAs .
In human neurons the APP695 isoform is the predominant expressed isoform. All APP isoforms (APP695, APP751 and APP770) share the same 3' UTR  therefore we expect that the mir-106a mediated regulation of APP levels that we observe in the HEK-293 cell line should also occur in neurons given that mir-106a is expressed in the brain. We do not expect mir-520c mediated APP regulation to occur in neurons since this miRNA is not expressed in brain. It is important to test if miRNA regulation is a normal aspect of APP metabolism in neurons. If so, it will be important to determine whether AD pathogenesis is affected by alterations in miRNA function and/or expression. It is possible that aging- or environment-induced changes in miRNA expression, and/or sequence variation in miRNAs or their targets, contribute to increased APP levels and increased AD risk. Recently, it was demonstrated that expression of the β-secretase BACE can be regulated by miR-29a/b-1 and mir-107; furthermore, increased BACE levels correlated with decreased miR-29a/b-1 and mir-107 levels in AD patients [19, 20].
Regardless of the biological roles of miRNA in APP metabolism, therapeutics based on miRNA-induced decrease in APP levels would offer a treatment targeting the underlying pathophysiology of the disease. In the near future, substantial progress will be made in understanding the role of miRNAs in AD pathogenesis and in therapeutic approaches to treating AD.
Reporter Vectors and DNA constructs
Reporter vectors containing the putative miRNA target sites from the APP 3'UTR, were synthesized with double-stranded oligos perfectly complementary to putative miRNA target sites and oligos in which the seed regions were mutated. The mir-106a target oligos had the sequence (seed region bolded):
5' CTAGTAATCCCTGTTCATTGTAAGCACTTTTGCTCAGCA 3'
3' ATTAGGGACAAGTAACATTCGTGAAAACGAGTCGTTCGA 5'
The mutant mir-106a target oligos had nucleotides three through six of the seed region mutated (italicized):
5' CTAGTAATCCCTGTTCATTGTAAGC GTCC TTGCTCAGCA 3'
3' ATTAGGGACAAGTAACATTCG CAGG AACGAGTCGTTCGA 5'
We utilized established methods  to clone these synthetic versions of putative miRNA target sites into a luciferase reporter gene (pMIR-REPORT; Ambion).
Cells and Cell Culture
Naïve human embryonic kidney (HEK)-293 cells were purchased from ATCC. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine,100 units/ml penicillin and 100 μg/ml streptomycin.
Transfections and Luciferase Assays
10,000 Naïve HEK-293 were plated in 24 well plates. The next day, cells were transfected with a miRNA overexpression vector , reporter vectors bearing either the miRNA target sequence or the miRNA seed region mutant target sequence, and one tenth of the molar volume of pRL-SV40, a Renilla Luciferase control vector. We utilized Arrest-In transfection reagent (Open Biosystems Inc.); any differences in transfection efficiency were accounted for by measuring Renilla luciferase activity. 48 hours post-transfection, cell were lysed using 100 μL of GLB (Glo Lysis Buffer, Promega). Firefly and Renilla luciferase activities were measured using a dual luciferase reporter assay kit (Promega), per the manufacturer's protocol. Firefly luciferase activity was normalized to Renilla luciferase activity.
Western Blot Analysis
200,000 Naïve 293 cells were plated in 6 well plates. The next day, cells were transfected with a miRNA overexpression vector. Using previously described methods , quantitative Western blots were performed using equal amounts of total protein.
A polyclonal antibody specific for the C-terminus of human APP (A8717; Sigma Aldrich, Inc) and a monoclonal antibody specific for human β-Actin (A5441; Sigma Aldrich) were used as primary antibodies. Secondary antibodies were HRP-conjugated goat anti-rabbit (GE Healthcare) and HRP-conjugated goat anti-mouse (GE Healthcare).
RNA extraction and Quantitative PCR
48 hours post-transfection, cells were washed with cold PBS and total RNA was isolated using RNeasy Mini Kit (Qiagen Inc.). To quantify APP mRNA levels, cDNA was synthesized using total RNA, N6 random primers and SuperScript II Reverse Transcriptase (Invitrogen). cDNA was then diluted 1:15 using RNase free water and mixed with APP or GAPDH primer/probe sets (Applied Biosystems, Inc.; APP Catalog # Hs00169098_m1; GAPDH Catalog # Hs99999905_m1), 2× PCR Universal Master Mix (Applied Biosystems, Inc.) and amplified using an ABI 7500 Real Time PCR system following the manufacturer's directions. GAPDH was used as an internal control. To determine differences in APP mRNA levels, we utilized the ΔΔCt method.
To quantify miRNA levels, cDNA was reverse transcribed from total RNA samples using specific miRNA primers from the TaqMan MicroRNA Assays and reagents from the Taq Man MicroRNA Reverse Transcription kit (Applied Biosystems). The resulting cDNA was amplified by PCR using TaqMan MicroRNA Assay primers with the TaqMan Universal PCR Master Mix and analyzed with a 7500 ABI PRISM Sequence Detector System (Applied Biosystems) according to the manufacturer's instructions. The relative levels of miRNA expression were calculated from the relevant signals by the ΔΔCt method by normalization to the signal of RNU44 .
Values in the text and figures are presented as means ± standard deviations of experiments carried out in triplicate, at least. Each experiment was carried three times. Equal variance or separate variance two-sample student's t-test were used, as appropriate, to compare two groups. Where appropriate, Bonferroni analysis was used to correct for multiple comparisons within a single experiment.
We would like to thank members of Saunders lab and Trinna Cuellar for comments on the manuscript. We would also like to thank Trinna Cuellar and Michael T. McManus for helpful discussions (RO3-DA022201). This work was funded by the NIH (AJS: R21NS48227), Commonwealth of Pennsylvania (AJS), and Drexel University (AJS).
- Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL: Amyloid a4 protein and its precursor in down's syndrome and alzheimer's disease. N Engl J Med. 1989, 320: 1446-1452.View ArticlePubMedGoogle Scholar
- Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C: APP duplication is sufficient to cause early onset alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006, 129: 2977-2983. 10.1093/brain/awl203.View ArticlePubMedGoogle Scholar
- Brouwers N, Sleegers K, Engelborghs S, Bogaerts V, Serneels S, Kamali K, Corsmit E, De Leenheir E, Martin JJ, De Deyn PP, Van Broeckhoven C, Theuns J: Genetic risk and transcriptional variability of amyloid precursor protein in alzheimer's disease. Brain. 2006, 129: 2984-2991. 10.1093/brain/awl212.View ArticlePubMedGoogle Scholar
- Rajagopalan LE, Malter JS: Growth factor-mediated stabilization of amyloid precursor protein mRNA is mediated by a conserved 29-nucleotide sequence in the 3'-untranslated region. J Neurochem. 2000, 74: 52-59. 10.1046/j.1471-4159.2000.0740052.x.View ArticlePubMedGoogle Scholar
- Rajagopalan LE, Westmark CJ, Jarzembowski JA, Malter JS: Hnrnp c increases amyloid precursor protein (APP) production by stabilizing APP mRNA. Nucleic Acids Res. 1998, 26: 3418-3423. 10.1093/nar/26.14.3418.PubMed CentralView ArticlePubMedGoogle Scholar
- Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN: Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J Biol Chem. 1999, 274: 6421-6431. 10.1074/jbc.274.10.6421.View ArticlePubMedGoogle Scholar
- Griffin WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE: The pervasiveness of interleukin-1 in alzheimer pathogenesis: A role for specific polymorphisms in disease risk. Exp Gerontol. 2000, 35: 481-487. 10.1016/S0531-5565(00)00110-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: Systematic meta-analyses of alzheimer disease genetic association studies: The alzgene database. Nat Genet. 2007, 39: 17-23. 10.1038/ng1934.View ArticlePubMedGoogle Scholar
- Pillai RS: MicroRNA function: Multiple mechanisms for a tiny RNA?. RNA. 2005, 11: 1753-1761. 10.1261/rna.2248605.PubMed CentralView ArticlePubMedGoogle Scholar
- Lukiw WJ: Micro-RNA speciation in fetal, adult and alzheimer's disease hippocampus. Neuroreport. 2007, 18: 297-300. 10.1097/WNR.0b013e3280148e8b.View ArticlePubMedGoogle Scholar
- John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human microRNA targets. LoS Biol. 2004, 2: e363-Google Scholar
- Liang Y, Ridzon D, Wong L, Chen C: Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007, 8: 166-10.1186/1471-2164-8-166.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R: The microRNAs mir-373 and mir-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008, 10: 202-210. 10.1038/ncb1681.View ArticlePubMedGoogle Scholar
- Carthew RW: Gene regulation by microRNAs. Curr Opin Genet Dev. 2006, 16: 203-208. 10.1016/j.gde.2006.02.012.View ArticlePubMedGoogle Scholar
- Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, Liebhaber SA, Pasquinelli AE, Shiekhattar R: MicroRNA silencing through risc recruitment of eif6. Nature. 2007, 447: 823-828. 10.1038/nature05841.View ArticlePubMedGoogle Scholar
- Niwa R, Zhou F, Li C, Slack FJ: The expression of the alzheimer's amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets in caenorhabditis elegans. Dev Biol. 2008, 315: 418-425.PubMed CentralView ArticlePubMedGoogle Scholar
- Westmark PR, Shin HC, Westmark CJ, Soltaninassab SR, Reinke EK, Malter JS: Decoy mRNAs reduce beta-amyloid precursor protein mRNA in neuronal cells. Neurobiol Aging. 2006, 27: 787-796. 10.1016/j.neurobiolaging.2006.03.003.View ArticlePubMedGoogle Scholar
- Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B: Loss of microRNA cluster mir-29a/b-1 in sporadic alzheimer's disease correlates with increased bace1/beta-secretase expression. Proc Natl Acad Sci USA. 2008, 105: 6415-6420. 10.1073/pnas.0710263105.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT: The expression of microRNA mir-107 decreases early in alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008, 28: 1213-1223. 10.1523/JNEUROSCI.5065-07.2008.PubMed CentralView ArticlePubMedGoogle Scholar
- Cheng AM, Byrom MW, Shelton J, Ford LP: Antisense inhibition of human mirnas and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33: 1290-1297. 10.1093/nar/gki200.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang C, Khandelwal PJ, Chakraborty R, Cuellar TL, Sarangi S, Patel SA, Cosentino CP, O'Connor M, Lee JC, Tanzi RE, Saunders AJ: An aicd-based functional screen to identify APP metabolism regulators. Mol Neurodegener. 2007, 2: 15-10.1186/1750-1326-2-15.PubMed CentralView ArticlePubMedGoogle Scholar
- Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE: MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008, 93: 1600-1608. 10.1210/jc.2007-2696.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.